NCT05701436View on ClinicalTrials.gov

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

January 1, 2026

Study Completion Date

March 1, 2026

Conditions
Liver, Cancer of, Primary Resectable
Interventions
DRUG

Oxaliplatin

130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

DRUG

Doxorubicin

20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

DRUG

Lobaplatin

50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

DRUG

Cisplatin

50 mg per square body surface area was used for monthly transhepatic arterial infusions.

DRUG

Oxaliplatin, Leucovorin, fluorouracil

Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.

DRUG

Lobaplatin, Raltitrexed

Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.

Trial Locations (1)

Unknown

RECRUITING

Zhujiang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
lead

Zhujiang Hospital

OTHER